Corporate Overview Includes Targeted Cancer Programs in Development,
Obatoclax and GMX1777
MALVERN, PA. & MONTREAL, November 7 /CNW/ - Gemin X Pharmaceuticals, Inc.
announced that Mr. Fred Banti, Vice-President Corporate Development, will
present a corporate overview at the BIO-Europe 2007 Partnering Conference on
Tuesday November 13, 2007 at 2:45 p.m. CET at the Congress Centre in Hamburg,
Germany. BIO-Europe is an international conference attended by delegates from
the biotechnology, pharmaceutical and financial sectors.
About Gemin X
Gemin X Pharmaceuticals, Inc., through its wholly-owned subsidiary Gemin
X Biotechnologies Inc., specializes in the discovery and development of
target-based novel cancer therapeutics. Gemin X's lead product, obatoclax
(GX15-070), is a small molecule, pan-inhibitor of Bcl-2 proteins and is
currently in Phase 2 clinical trials. Gemin X is also developing GMX1777, a
small molecule that targets cancer metabolism by a p53-independent mechanism,
now in Phase 1 clinical trials. Gemin X is privately held and is located in
Malvern, Pennsylvania and Montreal, Quebec. For additional information please
visit Gemin X at www.geminx.com.
For further information:
For further information: MacDougall Biomedical Communications Jennifer
Greenleaf, 508-647-0209 or Gemin X Biotechnologies Inc. Diane Viens,
514-281-8989 ext.387 email@example.com